GLOBAL CANCER TECHNOLOGY EXHIBITS AT THE ‘KUKUNA O KA LA’ RADIATION ONCLOGY CONFERENCE IN KONA

GLOBAL CANCER TECHNOLOGY EXHIBITS AT THE ‘KUKUNA O KA LA’ RADIATION ONCLOGY CONFERENCE IN KONA

Global Cancer Technology showcases GCT-007, it’s breakthrough PI3K inhibitor drug as an effective sensitizer to radiation treatments

San Diego, CA, April1, 2023 – Global Cancer Technology, Inc. announced today that it had successfully completed exhibiting at the annual Kukuna O Ka La Radiation Oncology meeting in Kona, Hawaii.

“We were excited to present our compelling pre-clinical data showing profound cell arrest and death when GTC-007 was administered followed by irradiation”, said John Clark, the CEO of Global Cancer Technology. “GCT-007 acts synergistically with radiation treatment to increase the sensitivity of the cells to immunotherapy” Mr. Clark further added.

“We were delighted to have Global Cancer Technology attend this year’s conference” said Dr. Andrew Chang, Radioation Oncologist, Vice-President of Kukuna O Ka La and President of the California Protons Center in San Diego. Dr. Chang further stated, “The Kukuna O Ka La Radiation Oncology Conference, attended by nationally recognized and leading Medical institutions, has become a premier platform for emerging medical companies to showcase their innovative technologies.”

The Kukuna O Ka La Radiation Oncology Conference is an annual meeting held in Hawaii that brings together nationally recognized luminaries presenting the latest advances in Radiation Oncology. The meeting is attended by Radiation Oncologists from North America and has become one of the most popular society meetings to attend.

Global Cancer Technology is a non-revenue biopharma company that is currently raising investment capital to enter a glioblastoma Phase 1 clinical trial.
Globalcancertechnology.com
Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company’s most recent shareholder letter. There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized.

Global Cancer Technology is working on a novel treatment for cancers, glioblastoma treatment technology and cancer inhibitors, know more about our cancer treatment technology.